Abstract: Provided herein are methods for determining polygenic traits and risks for medical use, such as cancer traits and risks, as well as treating diseases for which risk is identified and/or assessed. Methods of this invention can provide a polygenic score which takes into account local ancestry through the ancestral origin of the alleles of risk loci. A polygenic score can provide surprisingly increased accuracy in determining polygenic traits and risks for ancestrally admixed populations.
Type:
Application
Filed:
April 16, 2021
Publication date:
August 17, 2023
Applicant:
Myriad Genetics, Inc.
Inventors:
Dmitry Pruss, Alexander Gutin, Elisha Hughes, Jerry Lanchbury
Abstract: Provided herein are methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Type:
Application
Filed:
December 6, 2022
Publication date:
July 6, 2023
Applicant:
Myriad Genetics, Inc.
Inventors:
Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Abstract: Provided herein are methods for determining a polygenic risk score and breast cancer estimated risk for medical use, as well as for treating breast cancer. Methods of this invention can provide a polygenic risk score which takes into account a plurality of breast cancer associated SNP markers. Also provide is a comprehensive breast cancer risk estimation with increased accuracy.
Type:
Application
Filed:
April 16, 2021
Publication date:
June 1, 2023
Applicant:
Myriad Genetics, Inc.
Inventors:
Shannon Gallagher, Elisha Hughes, Alexander Gutin, Jerry Lanchbury
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Type:
Application
Filed:
December 14, 2022
Publication date:
April 20, 2023
Applicant:
Myriad Genetics, Inc.
Inventors:
Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Type:
Application
Filed:
December 14, 2022
Publication date:
April 13, 2023
Applicant:
Myriad Genetics, Inc.
Inventors:
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
Type:
Application
Filed:
October 14, 2022
Publication date:
April 13, 2023
Applicant:
Myriad Genetics, Inc.
Inventors:
Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
Abstract: This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.
Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
Type:
Grant
Filed:
March 4, 2020
Date of Patent:
November 22, 2022
Assignee:
MYRIAD GENETICS, INC.
Inventors:
Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Type:
Application
Filed:
October 12, 2021
Publication date:
June 30, 2022
Applicant:
Myriad Genetics, Inc.
Inventors:
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Abstract: The present disclosure relates to methods, kits, and systems for assessing the risk of a human subject for developing a cancer, including genetic risk assessment, clinical risk assessment, and combinations of both to improve risk analysis.
Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
Type:
Application
Filed:
September 24, 2021
Publication date:
April 14, 2022
Applicant:
Myriad Genetics, Inc.
Inventors:
Steven Stone, Alexander Gutin, Julia Reid
Abstract: Direct targeted sequencing (DTS) methods and a hidden Markov model (HMM) can be used to call the copy number of a segment of interest within a region of interest. Described herein are methods for calling a copy number variant or a copy number variant abnormality using an HMM, and methods for determining a copy number based on a copy number likelihood model, in a test sequencing library that has be sequenced using DTS methods. Also described herein are methods for determining a copy number of a segment, including accounting for spurious capture probes that may arise from the DTS methods.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
January 25, 2022
Assignee:
Myriad Genetics, Inc.
Inventors:
Kevin R. Haas, Xin Wang, Peter V. Grauman
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
November 16, 2021
Assignee:
MYRIAD GENETICS, INC.
Inventors:
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
November 16, 2021
Assignee:
Myriad Genetics, Inc.
Inventors:
Steven Stone, Alexander Gutin, Julia Reid
Abstract: The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
Type:
Application
Filed:
July 22, 2021
Publication date:
November 11, 2021
Applicant:
Myriad Genetics, Inc.
Inventors:
Kirsten Timms, Brian Allen, Anne-Renee Hartman
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Type:
Application
Filed:
June 21, 2021
Publication date:
October 7, 2021
Applicant:
Myriad Genetics, Inc.
Inventors:
Victor Abkevich, Kirsten Timms, Alexander Gutin